Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Abbott Owns Majority of Kos Shares

  • Abbott Laboratories has purchased a majority of Kos Pharmaceuticals’ outstanding shares and intends to offer $78 per remaining share. The transaction came after Abbott’s initial offer expired on December 12, 2006, and the company decided not to extend it.

    Abbott reports that it now owns about 91.4% of Kos' outstanding common stock. In November, Abbott offered to buy Kos for $3.7 billion to expand its presence in the lipid management market, provide several on-market products, and strengthen its late-stage pipeline, says Miles D. White, chairman and CEO. The cash tender offer was for $78 per share, a 56% premium over Kos’ closing price the day before.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »